Latest revenue
$0
as of 2023-03-31
Latest net income
$-4.5M
as of 2023-03-31
Net margin
—
as of 2023-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ELTX is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $252.1M
- Enterprise value
- $246.7M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $14.97
- 52-wk low
- $7.37
- Beta
- —
- Shares out
- 19.1M
5-year trend
What this company does
Item 1. Business Overview We are a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mutant Kirsten rat sarcoma viral oncogene homolog (“mKRAS”) - positive pancreatic cancer, colorectal cancer (“CRC”), lung cancer and other mKRAS positive cancers. We intend to build on recent clinical successes in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Our proprietary Amphiphile (“AMP”) technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance…
AI summary unavailable — showing raw filing excerpt
Generated from ELTX's filing dated 2026-03-12
Key risks
Table of Contents Item 1A. Risk Factors Investing in our securities involves a high degree of risk. You should carefully consider the risk factors set forth below as updated by our subsequent filings under the Exchange Act, before deciding whether to purchase our securities. The risks and uncertainties we describe below are not the only ones we face. Additional risks and uncertainties not presently known to us could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment. Summary Risk Factors We are…
AI summary unavailable — showing raw filing excerpt
Generated from ELTX's filing dated 2026-03-12
Profitability
Operating margin
-1721.9%
1140.3%Net margin
-1686.5%
775.0%Return on equity
-2418.8%
627.2%Return on assets
-153.0%
16.9%Leverage
Debt / equity
14.81×
524.2%Long-term debt / equity
5.75×
424.7%Debt / assets
93.7%
33.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-11.8M | -5.5% | — |
Q4 2025 2025-12-31 | — | — | $-7.7M | +44.9% | — |
Q3 2025 2025-09-30 | — | — | $-10.1M | +46.5% | — |
Q2 2025 2025-06-30 | — | — | $-10.6M | -46.1% | — |
Q1 2025 2025-03-31 | — | — | $-11.2M | +5.2% | — |
Q4 2024 2024-12-31 | — | — | $-14.0M | — | — |
Q3 2024 2024-09-30 | — | — | $-18.8M | -76.7% | — |
Q2 2024 2024-06-30 | — | — | $-7.2M | +4.4% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ELTX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ELTX
Institutional value
$8.9M
Total shares held
830.4K
Distinct holders
19
-18 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 518.6K | $5.5M | — | New |
| 2 | VANGUARD FIDUCIARY TRUST CO | 69.2K | $739.6K | — | New |
| 3 | BlackRock, Inc. | 50.6K | $540.9K | +5.4K (+12.0%) | Added |
| 4 | UBS Group AG | 33.8K | $361.0K | +1.8K (+5.5%) | Added |
| 5 | IRIDIAN ASSET MANAGEMENT LLC/CT | 30.1K | $321.2K | — | New |
| 6 | CM Management, LLC | 25.0K | $267.3K | +0 (+0.0%) | No change |
| 7 | Hudson Bay Capital Management LP | 20.2K | $216.0K | — | New |
| 8 | MEYER HANDELMAN CO | 13.9K | $148.6K | +0 (+0.0%) | No change |
| 9 | KINGSWOOD WEALTH ADVISORS, LLC | 13.8K | $147.5K | — | New |
| 10 | HighTower Advisors, LLC | 11.2K | $119.4K | -20 (-0.2%) | Trimmed |
| 11 | HB Wealth Management, LLC | 10.5K | $111.8K | — | New |
| 12 | Mayflower Financial Advisors, LLC | 10.0K | $106.9K | +0 (+0.0%) | No change |
| 13 | MOODY LYNN & LIEBERSON, LLC | 10.0K | $106.9K | +0 (+0.0%) | No change |
| 14 | BNP PARIBAS FINANCIAL MARKETS | 6.3K | $67.8K | +676 (+11.9%) | Added |
| 15 | Vanguard Global Advisers, LLC | 4.4K | $47.2K | — | New |
| 16 | Steward Partners Investment Advisory, LLC | 2.0K | $21.6K | +469 (+30.2%) | Added |
| 17 | Farther Finance Advisors, LLC | 721 | $7.7K | +16 (+2.3%) | Added |
| 18 | SBI Securities Co., Ltd. | 82 | $877 | +0 (+0.0%) | No change |
| 19 | Caitong International Asset Management Co., Ltd | 3 | $32 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ELTX's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.